宫颈癌免疫治疗的研究进展

Research Progress of Immunotherapy for Cervical Cancer

宫颈癌是最常见的妇科恶性肿瘤,其主要病因是高危型人乳头瘤病毒(HPV)持续感染。传统治疗方法包括手术、放疗及化疗,但是对于晚期、持续性或转移性宫颈癌疗效不容乐观。近年来治疗性疫苗、PARP抑制剂、免疫检查点抑制剂、过继T细胞疗法等免疫疗法的研究结果显示出良好的应用前景。全文对免疫检查点抑制剂、治疗性疫苗、工程TCR T细胞、PARP抑制剂等在宫颈癌中的相关临床试验及进展进行综述。

Cervical cancer is the most common gynecological malignancy. The persistent infection of high-risk human papillomavirus(HPV) is the main cause of cervical cancer. Traditional treatment methods include surgery, radiotherapy and chemotherapy, but the curative effect of advanced,persistent or metastatic cervical cancer is not optimistic. In recent years, the research results of therapeutic vaccines, PARP inhibitors, immune checkpoint inhibitors, adoptive T cell therapy and other immunotherapies have shown their good application prospects. This article reviews the clinical trials and researches progress of immune checkpoint inhibitors, therapeutic vaccines,TCR-engineered T cells and PARP inhibitors in cervical cancer.